Hussman Strategic Advisors Inc. Purchases New Shares in Medtronic PLC $MDT

Key Points

• Hussman Strategic Advisors purchased a new stake of 21,000 shares in Medtronic during Q4, valued at approximately $2.02 million.
• Medtronic has secured several regulatory wins — including the CE mark for the Stealth AXiS surgical system in Europe, FDA clearance for a next‑generation mitral valve, and progress in ablation device programs — which bolster its surgical robotics, cardiovascular, and neuromodulation growth prospects.
• Shares trade near the low end of their 12‑month range (opened at $80.02), the company has a market cap of about $102.7 billion and a 3.5% dividend yield, while analysts are mixed but show a consensus rating of Moderate Buy with a $107.80 price target.

Hussman Strategic Advisors Inc. purchased a new stake in Medtronic PLC (NYSE:MDT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 21,000 shares of the medical technology company's stock, valued at approximately $2,017,000.

Other large investors have also added to or reduced their stakes in the company. Corundum Trust Company INC bought a new stake in Medtronic in the third quarter valued at $27,000. Lodestone Wealth Management LLC bought a new stake in Medtronic in the fourth quarter valued at $27,000. Board of the Pension Protection Fund bought a new stake in Medtronic in the fourth quarter valued at $29,000. GoalVest Advisory LLC bought a new stake in Medtronic in the fourth quarter valued at $29,000. Finally, Valley Wealth Managers Inc. bought a new stake in Medtronic in the third quarter valued at $29,000. Institutional investors own 82.06% of the company's stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for the Stealth AXiS™ surgical system (spine & cranial); management frames the system as an integrated next‑generation navigation, planning and robotics platform that should help drive surgical growth and address hospital demand for consolidated systems. Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
• Positive Sentiment: CE mark in Europe for Stealth AXiS expands Medtronic’s addressable surgical market after earlier U.S. clearance — this supports the company’s surgical robotics/navigation growth story and creates new revenue opportunities in European hospitals. Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
• Positive Sentiment: Progress on cardiac rhythm devices: Affera’s Sphere‑9 FDA Breakthrough designation and related CE activity for ablation catheters highlight Medtronic’s expanding pulsed‑field and RF ablation portfolio — could boost future electrophysiology revenue if trials and approvals continue to progress. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: FDA cleared a next‑generation mitral valve, and Medtronic has enrolled the first patient in a post‑approval study for the Altaviva tibial neuromodulation system — both items support incremental product revenue and clinical validation across cardiovascular and neuromodulation franchises. Medtronic wins FDA nod for next-gen mitral valve Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Neutral Sentiment: Industry reports highlight wearable medical device market growth (Australia, Saudi Arabia) that could support long‑term opportunities for Medtronic’s wearable/remote monitoring initiatives, but these are broad market trends rather than company‑specific catalysts. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts
• Neutral Sentiment: Competitor and sector moves — Masimo published a large real‑world study on pulse oximetry accuracy across skin tones; Teleflex named a new CEO; Orchestra BioMed received another FDA Breakthrough designation. These items influence competitive and regulatory context but are not direct Medtronic earnings drivers. Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: Technical/market weakness: coverage noting MDT trading near multi‑month/1‑year lows highlights investor concern about valuation and near‑term momentum despite the product wins — this likely contributes to downward pressure on the stock. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch

Medtronic Stock Performance

Shares of MDT stock opened at $80.02 on Friday. Medtronic PLC has a 12 month low of $78.91 and a 12 month high of $106.33. The stock has a market cap of $102.74 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 2.08 and a beta of 0.62. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The company's fifty day moving average price is $88.44 and its 200-day moving average price is $94.81.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analysts' expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts expect that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic's payout ratio is currently 79.11%.

Analyst Ratings Changes

Several analysts recently weighed in on MDT shares. Piper Sandler cut their price target on shares of Medtronic from $105.00 to $91.00 and set a "neutral" rating on the stock in a report on Wednesday, April 1st. JPMorgan Chase & Co. dropped their target price on shares of Medtronic from $105.00 to $100.00 and set a "neutral" rating on the stock in a report on Wednesday, February 18th. UBS Group dropped their target price on shares of Medtronic from $104.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, April 22nd. Barclays boosted their target price on shares of Medtronic from $118.00 to $120.00 and gave the company an "overweight" rating in a report on Wednesday, April 1st. Finally, Daiwa Securities Group dropped their target price on shares of Medtronic from $117.00 to $115.00 and set a "buy" rating on the stock in a report on Friday, February 27th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $107.80.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company's stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.